{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:14:18Z","timestamp":1762460058528,"version":"3.41.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The World Health Organization (WHO) 2019 antiretroviral treatment guidelines recommend use of optimal treatment regimens in all populations. Dolutegravir-based regimens are the preferred first-line and second-line treatment in infants and children with HIV 4 weeks of age and above. There is an urgent need for optimal pediatric formulations of dolutegravir as single-entity (SE) and fixed-dose combination (FDC) to ensure correct dosing and adherence for swallowing and palatability. This article outlines the chronology of dolutegravir pediatric formulation development as granules and conventional and dispersible tablets in a total of 5 pharmacokinetic studies evaluating the relative bioavailability of dolutegravir SE and FDC formulations in healthy adults.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The relative bioavailability studies were 2-part, Phase I, open-label, randomized studies in healthy adults. Dolutegravir SE study compared conventional dolutegravir 50 and 25\u2009mg with equivalent conventional 10-mg and dispersible 5-mg tablets, respectively. Subsequently, dolutegravir FDC study compared adult FDC of abacavir\/dolutegravir\/lamivudine and adult FDC of dolutegravir\/lamivudine with their respective pediatric FDC formulations, taken as dispersion immediately or swallowed whole.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>As observed in previous studies, dolutegravir administered as dispersion (granules\/dispersible tablets) showed relatively higher bioavailability compared with conventional tablets. The bioavailability of dolutegravir dispersible tablets (both SE and FDC) was approximately 1.6-fold higher when compared with conventional tablets. In addition, the bioavailability of abacavir\/lamivudine was not impacted by dispersible formulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>These studies demonstrate the successful development of pediatric dolutegravir-containing formulations as SE and FDC that permit pediatric dosing in line with WHO recommendations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003366","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T15:08:55Z","timestamp":1637766535000},"page":"230-237","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children"],"prefix":"10.1097","volume":"41","author":[{"given":"Rajendra P.","family":"Singh","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly K.","family":"Adkison","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Baker","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Nyon, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ridhi","family":"Parasrampuria","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Wolstenholme","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Davies","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Ware, Hertfordshire, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Sewell","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Ware, Hertfordshire, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Brothers","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M.","family":"Buchanan","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/14656566.2017.1363180","article-title":"Developments in early diagnosis and therapy of HIV infection in newborns.","volume":"19","author":"Canals","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"suppl 1","key":"R4-20250615","doi-asserted-by":"crossref","first-page":"e25049","DOI":"10.1002\/jia2.25049","article-title":"Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries.","volume":"21","author":"Penazzato","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12879-019-4058-4","article-title":"Viral suppression rate among children tested for HIV viral load at the Amhara Public Health Institute, Bahir Dar, Ethiopia.","volume":"19","author":"Shiferaw","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QAI.0000000000001499","article-title":"HIV viral load suppression in adults and children receiving antiretroviral therapy\u2014results from the IeDEA collaboration.","volume":"76","author":"Jiamsakul","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12887-019-1599-z","article-title":"Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study).","volume":"19","author":"Fokam","year":"2019","journal-title":"BMC Pediatr"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"e15994","DOI":"10.1097\/MD.0000000000015994","article-title":"Clinical outcomes of a cohort of migrants and citizens living with human immunodeficiency virus in Botswana: implications for Joint United Nation Program on HIV and AIDS 90-90-90 targets.","volume":"98","author":"Marukutira","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/QAI.0000000000001859","article-title":"Effects of low- and high-mineral content water on the relative bioavailability of a coformulated abacavir\/dolutegravir\/lamivudine dispersible tablet in healthy adults.","volume":"79","author":"Singh","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/cpdd.332","article-title":"Relative bioavailability of a dolutegravir dispersible tablet and the effects of low- and high-mineral-content water on the tablet in healthy adults.","volume":"6","author":"Buchanan","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP2708","article-title":"Relative bioavailability of a paediatric granule formulation of the HIV integrase inhibitor dolutegravir in healthy adult subjects.","volume":"19","author":"Patel","year":"2014","journal-title":"Antivir Ther"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"e77448","DOI":"10.1371\/journal.pone.0077448","article-title":"Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.","volume":"8","author":"DeAnda","year":"2013","journal-title":"PLoS One"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"8458","DOI":"10.1021\/bi982870n","article-title":"Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase.","volume":"38","author":"Yi","year":"1999","journal-title":"Biochemistry"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/jac\/dkr139","article-title":"Pharmacokinetics of the HIV integrase inhibitor S\/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.","volume":"66","author":"Patel","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:00:43Z","timestamp":1750003243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003366","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2022,2,10]]}}}